Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.54 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.45 |
| ▸ | CHRNG | P07510 | 2/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.45 |
| ▸ | CHRND | Q07001 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19456877 | 0.87 | SSTR3 (0.54) | SSTR3CALCRLSIRT1SIRT2SIRT3 | |
| SCHEMBL23651238 | 0.85 | CALCRL (0.51) | SSTR3CALCRLCHRNA1CHRNGCHRNB1 | |
| SCHEMBL22267518 | 0.85 | CALCRL (0.49) | SSTR3CALCRLSIRT1CHRNA1CHRNG | |
| SCHEMBL23651237 | 0.85 | CALCRL (0.51) | SSTR3CALCRLCHRNA1CHRNGCHRNB1 | |
| SCHEMBL17706674 | 0.84 | SSTR3 (0.55) | SSTR3CALCRLSIRT1SIRT2SIRT3 | |
| SCHEMBL18494988 | 0.84 | SSTR3 (0.55) | SSTR3CALCRLSIRT1SIRT2SIRT3 | |
| SCHEMBL14821040 | 0.84 | SSTR3 (0.55) | SSTR3CALCRLSIRT1SIRT2SIRT3 | |
| SCHEMBL19403504 | 0.83 | SSTR3 (0.54) | SSTR3CALCRLSIRT1SIRT2SIRT3 | |
| SCHEMBL24829473 | 0.83 | SSTR3 (0.57) | SSTR3CALCRLSIRT1SIRT2SIRT3 | |
| SCHEMBL22910386 | 0.82 | CALCRL (0.51) | SSTR3CALCRLSIRT1SIRT2SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030592-A1 | Polyoxazoline Antibody Drug Conjugates | SERINA THERAPEUTICS (AL), INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030592-A1 | Polyoxazoline Antibody Drug Conjugates | FCGR2A, FCGR3B, FCGR1A | SSTR3 1343/4885CALCRL 4536/4885SIRT1 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.